Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 Combined With Standard Chemotherapy in First-line Treatment of Inoperable Malignant Mesothelioma
NCT05918107Phase 2Completed
- Sponsor
- Biotheus
- Start
- Aug 2022
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pumitamig in malignant mesothelioma, sponsored by Biotheus. Primary endpoints: Objective Response Rate at 2 years and Treatment related adverse events. Started Aug 2022; status: completed.
02
Drugs
pumitamig
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT05918107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918107.